Related Experiment Video
Updated: Jun 6, 2026
10:46
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Course of relapsing-remitting multiple sclerosis before, during and after natalizumab
Michael D Kaufman1, R Lee, H J Norton
1Carolinas Medical Center, Charlotte, NC 28207, USA. Michael.Kaufman@carolinashealthcare.org
Multiple Sclerosis (Houndmills, Basingstoke, England)
|December 8, 2010
Summary
Stopping natalizumab treatment leads to a rapid return of disease activity. Relapse rates increased significantly after treatment suspension, returning to pre-treatment levels.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Natalalizumab is an effective treatment for multiple sclerosis (MS).
- The effects of discontinuing natalizumab therapy are not fully understood.
- Understanding relapse rates after natalizumab cessation is crucial for patient management.
Purpose of the Study:
- To evaluate confirmed annualized relapse rates in patients before, during, and after natalizumab therapy suspension.
- To quantify the impact of natalizumab interruption on disease activity.
Main Methods:
- A retrospective chart review was performed.
- Data on relapse rates were analyzed using Generalized Estimating Equations.
- Confirmed and unconfirmed relapse rates were assessed.
Main Results:
- The confirmed annualized relapse rate during natalizumab therapy was 0.08.
- Relapse rates increased to 0.52 in the 12 months prior to therapy and 0.35 in the 3-24 months following cessation.
- These increases were statistically significant (p = 0.0003 and p = 0.0032, respectively).
Conclusions:
- Disease activity in multiple sclerosis patients rapidly returns to pre-natalizumab levels after treatment cessation.
- Natalalizumab discontinuation is associated with a significant increase in relapse rates.
- These findings highlight the importance of continuous natalizumab therapy for sustained disease control.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...